Core Viewpoint - Johnson & Johnson is currently under observation due to its stock performance and potential future direction, particularly in relation to earnings estimates and revenue growth [1][2]. Earnings Estimate Revisions - For the current quarter, Johnson & Johnson is expected to report earnings of $2.64 per share, reflecting a decrease of -6.4% year-over-year, with a slight increase of +0.5% in the Zacks Consensus Estimate over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is $10.62, indicating a growth of +6.4% from the previous year, with a minor adjustment of +0.1% in the last month [5]. - For the next fiscal year, the earnings estimate stands at $11, suggesting a growth of +3.6% compared to the prior year, with a recent increase of +0.2% [6]. - Johnson & Johnson holds a Zacks Rank 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $22.77 billion, representing a year-over-year increase of +1.4% [11]. - For the current fiscal year, the revenue estimates are $91.19 billion and $94.24 billion, indicating growth rates of +2.7% and +3.4%, respectively [11]. Last Reported Results and Surprise History - In the last reported quarter, Johnson & Johnson achieved revenues of $21.89 billion, a year-over-year increase of +2.4%, and an EPS of $2.77, up from $2.71 a year ago [12]. - The company exceeded the Zacks Consensus Estimate for revenues by +1.26% and for EPS by +7.78% [12]. - Johnson & Johnson has consistently beaten consensus EPS and revenue estimates over the past four quarters [13]. Valuation - Johnson & Johnson is graded B in the Zacks Value Style Score, indicating it is trading at a discount compared to its peers [17].

MicroStrategy (MSTR) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this business software company have returned +1.3% over the past month versus the Zacks S&P 500 composite's +5.1% change. The Zacks Computer - Software industry, to which MicroStrategy belongs, has gained 8.8% over this period. Now the key question is: Where could the stock be headed in ...

Wix.com (WIX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this cloud-based web development company have returned -14.2%, compared to the Zacks S&P 500 composite's +6.9% change. During this period, the Zacks Computers - IT Services industry, which Wix.com falls in, has gained 2.7%. The key question now is: What could be the stock's ...

GE Vernova (GEV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this the energy business spun off from General Electric have returned +30.8%, compared to the Zacks S&P 500 composite's +6.7% change. During this period, the Zacks Alternative Energy - Other industry, which GE Vernova falls in, has gained 17%. The key question now is: Wh ...

GE Vernova (GEV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this the energy business spun off from General Electric have returned +31.9%, compared to the Zacks S&P 500 composite's +9% change. During this period, the Zacks Alternative Energy - Other industry, which GE Vernova falls in, has gained 22.2%. The key question now is: Wh ...

Core Viewpoint - Boston Scientific (BSX) has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimate Revisions - For the current quarter, Boston Scientific is expected to report earnings of $0.72 per share, reflecting a year-over-year increase of +16.1% [5] - The Zacks Consensus Estimate for the current fiscal year is $2.91, indicating a year-over-year change of +15.9%, with a +2.2% revision over the last 30 days [5] - The consensus earnings estimate for the next fiscal year is $3.26, showing a change of +11.8% from the previous year, with a +0.9% revision over the past month [6] - Boston Scientific holds a Zacks Rank 2 (Buy), suggesting a favorable outlook based on recent earnings estimate changes [7] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.89 billion, indicating a year-over-year increase of +18.6% [11] - For the current fiscal year, the sales estimate is $19.49 billion, reflecting a change of +16.4%, while the next fiscal year's estimate is $21.55 billion, indicating a +10.6% change [11] Last Reported Results and Surprise History - In the last reported quarter, Boston Scientific achieved revenues of $4.66 billion, a year-over-year increase of +20.9%, and an EPS of $0.75 compared to $0.56 a year ago [12] - The company exceeded the Zacks Consensus Estimate for revenues by +2.31% and for EPS by +11.94% [12] - Boston Scientific has consistently beaten consensus EPS and revenue estimates over the past four quarters [13] Valuation - Boston Scientific is graded D on the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [17] - Valuation metrics such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued, fairly valued, or undervalued [15][16] Bottom Line - The information presented suggests that Boston Scientific may outperform the broader market in the near term, supported by its Zacks Rank 2 [18]

Core Viewpoint - Arch Capital Group (ACGL) has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimates - Arch Capital is expected to report earnings of $2.34 per share for the current quarter, reflecting a year-over-year decline of 9% [5] - The consensus earnings estimate for the current fiscal year is $7.89, indicating a year-over-year decrease of 15% [5] - For the next fiscal year, the consensus earnings estimate is $9.57, showing a year-over-year increase of 21.2% [6] - Over the last 30 days, the earnings estimates have seen slight changes of -1.8% for the current quarter and -0.1% for the current fiscal year [5][6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.68 billion, representing a year-over-year increase of 18.8% [11] - For the current fiscal year, the revenue estimate is $18.91 billion, indicating a growth of 13.8%, while the next fiscal year is projected at $20.32 billion, reflecting a growth of 7.5% [11] Last Reported Results and Surprise History - In the last reported quarter, Arch Capital achieved revenues of $4.56 billion, a year-over-year increase of 21.3% [12] - The EPS for the same period was $1.54, down from $2.45 a year ago, with a surprise of +12.41% compared to the consensus estimate [12][13] - The company has consistently beaten consensus EPS estimates in the last four quarters and topped revenue estimates three times [13] Valuation - Arch Capital has a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [7][18] - The Zacks Value Style Score for Arch Capital is graded B, indicating it is trading at a discount compared to its peers [17]

Core Viewpoint - Novo Nordisk's stock has experienced a decline of -2.2% over the past month, underperforming the Zacks S&P 500 composite's -0.5% change and the Zacks Large Cap Pharmaceuticals industry's -2% loss, raising questions about its near-term performance [1] Earnings Estimate Revisions - The consensus earnings estimate for the current quarter is $0.91 per share, reflecting a year-over-year increase of +9.6%, with a recent change of +2.2% over the last 30 days [4] - For the current fiscal year, the consensus earnings estimate is $3.85, indicating a +17.4% change from the previous year, with a +1.3% change in the last 30 days [4] - The next fiscal year's consensus earnings estimate is $4.71, showing a +22.4% change from the prior year, with a +2.1% change over the past month [5] - Novo Nordisk holds a Zacks Rank 3 (Hold), influenced by recent changes in consensus estimates and other earnings-related factors [6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $11.33 billion, indicating a year-over-year increase of +19.1% [10] - The sales estimates for the current and next fiscal years are $50.66 billion and $58.15 billion, reflecting changes of +20.3% and +14.8%, respectively [10] Last Reported Results and Surprise History - In the last reported quarter, Novo Nordisk achieved revenues of $12.26 billion, a year-over-year increase of +28.9%, and an EPS of $0.91 compared to $0.71 a year ago [11] - The reported revenues exceeded the Zacks Consensus Estimate of $11.34 billion by +8.11%, and the EPS surprise was +9.64% [11] - Over the last four quarters, Novo Nordisk surpassed consensus EPS estimates twice and revenue estimates twice [12] Valuation - Novo Nordisk is graded B in the Zacks Value Style Score, indicating it is trading at a discount to its peers [16]

Core Viewpoint - Costco has been trending positively in the stock market, outperforming the S&P 500 and the discount retail industry, raising questions about its future stock performance [1] Earnings Estimate Revisions - The current quarter's earnings estimate for Costco is $4.25 per share, reflecting a year-over-year increase of +12.4% with a recent change of +0.5% in the consensus estimate [4] - For the current fiscal year, the consensus earnings estimate is $17.96, indicating a change of +11.5% from the previous year, with a slight change of +0.1% over the last 30 days [4] - The next fiscal year's consensus earnings estimate stands at $19.73, showing a change of +9.9% from the prior year, with no change in the estimate over the past month [5] Revenue Growth Forecast - Costco's consensus sales estimate for the current quarter is $63 billion, representing a year-over-year change of +7.7% [10] - The sales estimates for the current and next fiscal years are $274.3 billion and $292.89 billion, indicating changes of +7.8% and +6.8%, respectively [10] Last Reported Results and Surprise History - In the last reported quarter, Costco achieved revenues of $63.72 billion, a year-over-year increase of +9%, with an EPS of $4.02 compared to $3.71 a year ago [11] - The reported revenues exceeded the Zacks Consensus Estimate of $63.22 billion by +0.79%, while the EPS fell short by -1.71% [11] - Over the last four quarters, Costco surpassed consensus EPS estimates three times and revenue estimates two times [12] Valuation - Costco is graded D in the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [16] - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether Costco's stock is overvalued or undervalued [14][15] Bottom Line - The information presented may assist in evaluating the market interest surrounding Costco, with a Zacks Rank of 3 suggesting it may perform in line with the broader market in the near term [17]

PepsiCo (PEP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this food and beverage company have returned -9.1%, compared to the Zacks S&P 500 composite's -0.7% change. During this period, the Zacks Beverages - Soft drinks industry, which PepsiCo falls in, has lost 1.4%. The key question now is: What could be the stock's future direc ...